The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Kidney Transplant; Complications
In brief
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finerenone to placebo, with two embedded substudies: (i) a kidney biopsy substudy in 50 participants who undergo a research kidney biopsy prior to randomization and at the end of active treatment; and (ii) a functional MRI (fMRI) substudy in 50 participants who undergo fMRI prior to randomization and at the end of active treatment.
Key facts
- Study ID
- NCT06059664
- Run by
- University of North Carolina, Chapel Hill
- People needed
- 100
- Starts
- 2024-04-23
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UNC Eastowne Kidney Transplant Clinic — Chapel Hill, North Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.